Derivation Web

source_b78beaadbfe94573

by researka:v2 · 2026-06-26 09:16:28.006180+04:00

{"contradictions": ["Methodologically, the synthesis is dominated by indirect, review, and protocol-level evidence with comparatively few direct RCTs, and the available human data do not yet adjudicate whether subgroup-specific signals (e. For example, the adverse detraining effects in Zheng 2025 versus the null influenza-vaccine cardiovascular subgroup effects in Nielsen 2026) reflect genuine heterogeneity versus design-driven noise.", "The geroscience hypothesis argues that targeting the molecular hallmarks of aging may yield larger and more synchronised gains across organ systems than the current strategy of treating each chronic disease in isolation. Within that frame, cardiovascular subgroups are attractive because the cardiovascular system is both measurable (through blood pressure, lipids, vascular function, and hard events) and mechanistically entangled with pathways implicated in aging biology such as inflammation, metabolic regulation, and fibrosis. A practical appeal is that several candidate agents are already licensed for cardiovascular or metabolic indications, so the choice between repurposing and novel development can in principle be answered through pragmatic trials in cardiovascular subgroups rather than de novo drug development. Whether the geroscience bet actually translates into clinical cardiovascular benefit remains uncertain, however, because trials designed around aging biology endpoints have only recently entered the cardiovascular subgroups pipeline. The cardiovascular subgroups anti-aging case, as currently constituted, therefore rests on a mix of mechanistic plausibility and indirect human evidence rather than on dedicated trials.", "source-grounded cardiovascular subgroups in this evidence base span multiple drug classes, including sodium-glucose cotransporter 2 inhibitors, cholesteryl ester transfer protein inhibitors, influenza vaccination strategies, and antithrombotic regimens. SGLT2 inhibitors have an established cardiometabolic regulatory history and are being examined in older adults with cardiovascular disease (Minami 2025), while the CETP inhibitor obicetrapib has been studied at the 10 mg daily dose in the BROADWAY trial programme with secondary mechanistic readouts (Davidson 2025). Influenza vaccination has a different access pathway: high-dose versus standard-dose formulations are being compared for severe cardiovascular outcomes in older adults with diabetes (Nielsen 2026), and the regulatory history of these vaccines means the cardiovascular subgroups case can be tested without the long safety runway required for novel small molecules. Within antiplatelet and antithrombotic care, extended follow-up of the ASPREE cohort has evaluated aspirin for primary prevention in adults aged 70 years and over (Wolfe 2025). The cardiovascular subgroups rationale, then, is partly that the infrastructure and labelling for these agents already exist, which may shorten the path from hypothesis to actionable prescribing.", "Several unresolved questions remain at the centre of the cardiovascular subgroups debate. First, the translation from mechanistic signal to functional and hard-outcome benefit is uncertain: the same intervention can move a surrogate biomarker while leaving clinical cardiovascular events unchanged, and Ioannidis 2005 cautions against treating surrogate endpoints as proxies for hard-outcome validity. Second, treatment effects appear to differ across subgroups, with frailty status emerging as a recurring modifier of cardiovascular benefit, and sarcopenia-related cohorts in this source set reporting elevated cardiovascular risk and mortality (Zhang 2025). Third, tradeoffs between benefit and harm, including bleeding, polypharmacy burden, and drug–drug interactions, are not uniformly characterised in older or multimorbid cardiovascular subgroups populations (Lee 2026). Fourth, follow-up durations in many of the included trials and reviews are short relative to the lifespan arc that an aging-targeted cardiovascular subgroups strategy would need to address, and dose–response relationships remain poorly mapped in frail subgroups. Whether cardiovascular subgroups effects can be sustained, or amplified, with longer follow-up remains uncertain.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "Source-label disambiguation note: citation label Chen (2026a) maps to one retained manifest receipt (Longevity; direction=mixed; directness=indirect; title: The Relationship between Sarcopenia and All-Cause and Cardiovascular Mortality Risk among Middle-Aged and Older Adults across Stages 0–3 of Cardiovascular-Kidney-Metabolic Syndrome: Evidence from NHANES and CHARLS); citation label Chen (2026b) maps to one retained manifest receipt (Longevity; direction=unclear; directness=indirect; title: Resting Heart Rate as a Non-Cardiovascular Mortality Marker in Young Adults: A Population-Based Cohort Study); citation label Ward (2026) maps to one retained manifest receipt (Immune and Inflammation; direction=null; directness=indirect; title: Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes); citation label Filev (2026) maps to one retained manifest receipt (Immune and Inflammation; direction=unclear; directness=indirect; title: Association of Acute-Phase IL-6 and SAA with Cardiovascular Events and Mortality Six Years After COVID-19 Infection: An Observational Cohort Study)."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "a1bcd190-f6e6-43c4-8621-4ce37971859a", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 64, "included": 64, "included_or_retained": 64, "screened": 64, "wording": "64 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "a1bcd190-f6e6-43c4-8621-4ce37971859a",
  "researka_submission_id": "fc0e622a-e286-4c53-a092-d1c214126947",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/a1bcd190-f6e6-43c4-8621-4ce37971859a/sidecars/contradiction_map.json"
}